FOR US HEALTHCARE PROFESSIONALS ONLY
For adults living with schizophrenia
Repeated relapses and cycles of failure on oral antipsychotics can shatter lives
SYMPTOM STABILITY
CAN’T WAIT
See how INVEGA SUSTENNA® can provide patients
with superior symptom control today
Actor Portrayal.
Help avoid cycles of repeated relapses associated with daily orals with INVEGA SUSTENNA®—the #1 prescribed LAI.1
Evaluated vs placebo and compared to groups of oral antipsychotics
Evaluated in over 2,500 patients across 7 trials
Initiate, maintain, and adjust dosing—and how to transition patients to INVEGA SUSTENNA®
Transitioning from other antipsychotics
A step-by-step guide for preparing and administering INVEGA SUSTENNA®
Trust what you know
Prescribe INVEGA SUSTENNA® today
SUPERIORITY
INVEGA SUSTENNA® is the only* LAI with proven superiority vs a group of orals2,3†
RELIABILITY
INVEGA SUSTENNA® has a proven efficacy and safety profile, prescribed by mental health providers for >15 years2-6
AFFORDABILITY
INVEGA SUSTENNA® is widely covered‡ and may cost as low as $0 per month for government-insured patients 7,8‡§||¶#
*Only Johnson & Johnson conducted these clinical trials.
†The oral antipsychotics accounted for 74% of oral schizophrenia treatment during the study period.9 Primary endpoint: Time to first treatment failure. The 5 most common AEs in the INVEGA SUSTENNA® group were: injection-site pain (18.6%), insomnia (16.8%), weight increase (11.9%), akathisia (11.1%) and anxiety (10.6%).3
LAI=long-acting injectable; LIS=Low-Income Subsidy.
‡Widely covered is defined as >65% number of covered lives. Managed Markets Insights and Technology, LLC™, a trademark of MMIT, as of February 2025. Collected as of February 2025 and may change.
§This information is not a promise of coverage or payment. It is not intended to give reimbursement advice or increase reimbursement by any payer. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, reimbursement policies, restrictions, or requirements that may apply.
||The Medicaid out-of-pocket cost range for generic oral antipsychotics in 2019 was $0.00–$343.06 and the range for INVEGA SUSTENNA® was $0.00–$348.41. 95% of the patients on generic oral antipsychotics paid $3.13 or less, and 95% of patients on INVEGA SUSTENNA® paid $3.36 or less.10 The Medicare Part D LIS out-of-pocket cost range for generic oral antipsychotics in 2019 was $0.00–$40.80 and the range for all second-generation long-acting injectables (eg, INVEGA SUSTENNA®) was $0.00–$34.00.8
¶Medicare Part D LIS patients who paid $0 were institutionalized. Noninstitutionalized patients paid as low as $15.20 per month.8
#See Access and Affordability page for more information.
References: 1. Data on file. Janssen Pharmaceuticals, Inc. 2. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 4. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 5. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. 6. Center for Drug Evaluation and Research. Approval letter. July 31, 2009. Accessed November 19, 2025. www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000Approv.pdf. 7. Lin D, Pilon D, Benson C, et al. PMH7: Assessment of patient out-of-pocket costs for antipsychotic treatments among Medicaid beneficiaries with schizophrenia. Poster presented at: ISPOR 2021; May 17-20, 2021; Virtual. 8. Li P, Benson C, Zhi Geng Z, et al. Out-of-pocket costs for long-acting injectable and oral antipsychotics among full Low-Income Subsidy (LIS) Medicare beneficiaries with schizophrenia. Poster presented at: Psych Congress Elevate. June 3-5, 2022. Las Vegas, NV. 9. Data on file. Janssen Pharmaceuticals, Inc. 10. Data on file. Janssen Pharmaceuticals, Inc.